Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

CAP-IT Center for LNP RNA Immunoprevention

Award Number: U54CA272688
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: COOPERATIVE AGREEMENT
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/01/2022
PERIOD OF PERFORMANCE END DATE: 08/31/2027

Group Awards By:

View Award Description

CAP-IT Center for LNP RNA Immunoprevention - The overall goal of CAP-IT Center for Immunoprevention (CRI) is to pre-clinically delineate, formulate and validate nucleic acid vaccines for precision prevention of individuals with increased cancer risk. The PI is Dr. Lipkin, an established leader in Cancer Prevention who has made several important, clinically translated contributions to the field. Project 1 will develop and validate an immunoprevention vaccine for Lynch syndrome, a genetic cancer predisposition syndrome with highly immunogenic recurrent neoantigens shared among cancers from different patients. Project 2 will develop and validate a nucleic acid immune interception vaccine for patients with lung non-solid nodule (NSN) pre-malignant neoplasms, a lung adenocarcinoma precursor lesion. To achieve these goals, we will use state-of-the-art technologies, including nucleic acid vaccine formulation, computational genomic tumor immunology, spatial genomics and immunopeptidomics. To ensure CRI's scientific rigor and excellence, we have assembled a scientifically outstanding CRI External Advisory Board (EAB). Overall, the CAP-IT CRI will develop state-of-the-art nucleic acid immunoprevention and immune interception vaccines and provide a technologically powerful platform to jumpstart additional CAP-IT CRI vaccine projects. We anticipate that CAP-IT CRI will propel both Lynch syndrome and lung NSN vaccines to NCI PREVENT and CP-NET clinical trials and FDA approval/clinical translation.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $0 )
2026	2025	WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY	575 LEXINGTON AVE FL 9	NEW YORK	NY	10022	NEW YORK	USA	Cancer Control	000	4	12/23/2025	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2025 ( Subtotal = $1,315,413 )
2025	2025	WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY	575 LEXINGTON AVE FL 9	NEW YORK	NY	10022	NEW YORK	USA	Cancer Control	000	4	9/1/2025	NON-COMPETING CONTINUATION	$1,315,413
														Subtotal = $1,315,413

Issue Date FY: 2024 ( Subtotal = $1,060,438 )
2024	2024	WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY	575 LEXINGTON AVE FL 9	NEW YORK	NY	10022	NEW YORK	USA	Cancer Control	001	3	8/8/2024	NON-COMPETING CONTINUATION	$1,060,438
2024	2023	WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY	575 LEXINGTON AVE FL 9	NEW YORK	NY	10022	NEW YORK	USA	Cancer Control	000	2	4/16/2024	NON-COMPETING CONTINUATION	$0
														Subtotal = $1,060,438

Issue Date FY: 2023 ( Subtotal = $1,098,880 )
2023	2023	WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY	1300 YORK AVE	NEW YORK	NY	10065	NEW YORK	USA	Cancer Control	000	2	8/11/2023	NON-COMPETING CONTINUATION	$1,098,880
														Subtotal = $1,098,880

Issue Date FY: 2022 ( Subtotal = $1,180,595 )
2022	2022	WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY	1300 YORK AVE	NEW YORK	NY	10065	NEW YORK	USA	Cancer Control	000	1	8/29/2022	NEW	$1,180,595
														Subtotal = $1,180,595

Grand Total All Awards = $4,655,326

Top

All Categories

About

Search

Reports

Data Submission

Award Information

CAP-IT Center for LNP RNA Immunoprevention

Award Number: U54CA272688

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: COOPERATIVE AGREEMENT

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/01/2022

PERIOD OF PERFORMANCE END DATE: 08/31/2027

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer